This post was originally published on this site
Moderna and the U.S. government agency had entered into a license agreement in December related to certain patents concerning the COVID vaccine products, the filing showed.
The vaccine maker first disclosed the deal in its fourth-quarter earnings release stating it missed profit estimates hurt by the royalty payment to NIH.
Moderna said under the agreement it would pay low single-digit royalties on future net sales and also minimum annual royalties.
